IV NAD+ and your mitochondria: what a new peer-reviewed review actually concludes
·IV NAD+ drips are sold in wellness clinics with promises that run well ahead of the science — more energy, sharper brains, slower aging. A new narrative review in Frontiers in Aging, surveying human literature from January 2018 through March 2026, does something unusual in this space: it takes the mitochondrial rationale seriously and the clinical claims apart. The result is the most even-handed assessment the IV NAD+ literature has had in a while.
Why NAD+ matters to mitochondria
The mechanistic case is genuinely strong. NAD+ is an indispensable coenzyme for mitochondrial energy metabolism — a substrate for sirtuins, PARPs and CD38 — and SIRT1, the best-known sirtuin, deacetylates PGC-1α, the master switch of mitochondrial biogenesis. In plain terms: NAD+ sits upstream of the machinery that builds new mitochondria and tunes how existing ones burn fuel. Preclinical work consistently shows NAD+ augmentation influencing energy metabolism, oxidative stress and inflammatory signaling.
The review also flags a wrinkle the marketing skips: a large cross-sectional study found whole-blood NAD+ concentrations were not independently associated with chronological age once disease burden was accounted for. If age alone doesn't predict NAD+ deficiency, then "you're over 40, you need a drip" is not a scientific argument — trials, the authors suggest, should screen by actual NAD+ status rather than birth year.
What the review found in human studies
Here the ground gets thin. The available human evidence is sparse: small uncontrolled studies, observational reports and isolated case reports. Short-term IV NAD+ or NMN administration has been associated with transient increases in circulating NAD+ and changes in selected biomarkers of oxidative stress, inflammation and metabolism — but the clinical significance is uncertain, with small samples, no placebo controls, heterogeneous methods and short follow-ups. Reported side effects include nausea, cramping, flushing and chest discomfort; long-term safety data are lacking.
Two pharmacological caveats stand out. First, IV NAD+ is partly broken down in the bloodstream (notably by the enzyme CD38) before cells can take it up, so it remains uncertain how much intact NAD+ actually reaches the inside of cells versus arriving as metabolites. Second, while IV delivery bypasses gut absorption and first-pass metabolism, direct evidence that it outperforms oral precursors is currently lacking — and many commercial infusion protocols have never undergone formal clinical validation.
The honest bottom line
The review's conclusion is blunt: current evidence on IV NAD+ "remains preliminary and insufficient to support routine clinical or wellness use," and larger randomized trials with standardized protocols are needed before it can be considered evidence-based practice. The literature, it warns, should be regarded as hypothesis-generating rather than practice-changing — particularly in wellness settings where marketing has outrun the data.
That is not the same as saying the idea is dead. The mitochondrial rationale — electron-transport support, sirtuin activation, biogenesis signaling — is biologically coherent and worth testing properly. But until trials measure real clinical endpoints in well-chosen patients, IV NAD+ belongs in the "promising mechanism, unproven therapy" column. Our evidence grade reflects exactly that.
Where the evidence stands
- Established: NAD+ is essential for mitochondrial energetics; the SIRT1–PGC-1α biogenesis axis is well-characterized biology.
- Preliminary: Small human studies show transient NAD+ increases and biomarker shifts after IV NAD+/NMN, with uncertain clinical meaning.
- Absent: No large randomized trials of IV NAD+; no long-term safety data; no demonstrated superiority over oral precursors; routine wellness use unsupported.